Loading…
Loading…
ICUI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for ICUI and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for ICUI and 80,000+ other tickers.
See exactly how ICUI's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ICUI and 80,000+ other tickers.
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system…
SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2026 earnings release and conference call.
Beta Bionics (NASDAQ: BBNX - Get Free Report) and ICU Medical (NASDAQ: ICUI - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk. Risk and Volatility Beta Bionics has a beta
Here, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.
ICU Medical, Inc. (NASDAQ: ICUI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to
On September 22, 2026, ICU Medical Inc (ICUI) shares rose 3.7%, bringing the current price to $160.98. The stock has fluctuated within a 52-week range of $112.5